Novavax, Inc. appears to be producing COVID-19 vaccine candidates at risk in order to be able to ensure their protein-based shot is ready in time for an expected fall booster campaign.
US Food and Drug Administration officials and its Vaccines and Related Biological Products Advisory Committee are scheduled to meet







